根據(jù)2005年11月發(fā)表在《腎臟疾病臨床實(shí)踐》的研究報(bào)道，碳酸鑭(Fosrenal)對(duì)終末期腎臟疾病(ESRD)患者而言，是一種安全的、耐受性很好的藥物，能夠在70％患者中降低并維持平均血清磷酸鹽水平達(dá)3年之久。

對(duì)全球?qū)⒔?百萬(wàn)面臨高磷酸血癥嚴(yán)重并發(fā)癥危險(xiǎn)的患者而言，這些研究結(jié)果是令人振奮的消息，高磷酸血癥是血液中出現(xiàn)過(guò)量磷酸鹽所導(dǎo)致的疾病。這種疾病是許多ESRD患者幾乎不可避免的結(jié)果，在許多患者沒(méi)有得到有效治療。接受血液透析的患者低磷酸鹽飲食是十分必要的，但是對(duì)許多嚴(yán)格控制飲食，血中磷酸鹽水平仍然升高。

如果不能有效治療，高磷酸鹽血癥會(huì)導(dǎo)致腎性骨營(yíng)養(yǎng)不良，或者導(dǎo)致心血管疾病，這幾乎導(dǎo)致半數(shù)接受透析治療患者的死亡。Fosrenal通過(guò)結(jié)合消化道食物中的磷酸鹽來(lái)發(fā)揮作用。一旦結(jié)合Fosrenal復(fù)合物不能通過(guò)腸道而進(jìn)入血液，從而被機(jī)體排除體外，顯著地降低磷酸鹽的吸收。Fosrenal是由英國(guó)Shire全球臨床醫(yī)學(xué)(Basingstoke, UK)公司研制開(kāi)發(fā)的。

Drug Aids Renal Patients Long Term
 
Lanthanum carbonate (Fosrenal) has been found to be safe and tolerable in patients with end-stage renal disease (ESRD) while successfully reducing and maintaining mean serum phosphate levels in 70% of patients for up to three years, according to a study in the November 2005 issue of Nephron Clinical Practice.

These results are promising news for the nearly one million people worldwide at risk for the serious consequences of hyperphosphatemia, a condition caused by an excess amount of phosphate in the blood. The condition is an almost inevitable consequence of ESRD and remains poorly controlled in many patients. A low phosphate diet is essential for managing dialysis patients but many have highly elevated levels despite maintaining a strict diet.

If not well-managed, hyperphosphatemia can cause renal osteodystrophy or contribute to cardiovascular disease, which accounts for almost half of all deaths among dialysis patients. Fosrenal works by binding to dietary phosphate in the gastrointestinal tract. Once bound, the Fosrenal complex cannot pass through the intestinal lining into the bloodstream and is eliminated from the body, decreasing phosphate absorption significantly. Fosrenal was developed by Shire Global Clinical Medicine (Basingstoke, UK).